The Carlat Psychiatry Podcast

A concise forensic look at psychiatric labels used for Jeffrey Epstein, including psychopathy scores and dark triad dynamics. Discussion of whether his actions reflect pedophilia, hebephilia, or antisocial motives. Explanation of DSM distinctions and offender study data. Brief detour into extra virgin olive oil research, mechanisms, and product quality tips.

They analyze psychiatric labels tied to Jeffrey Epstein, including narcissism, antisocial traits, and the dark triad. They probe ambiguous circumstances around his death and the role of guards. They trace his career, financial schemes, and why elites paid him. They discuss forensic postmortem diagnosis, cultural spread of dark triad terms, and therapies aimed at reducing aggression and teaching empathy.

They trace the Epstein and Maxwell relationship, early abuse reports, and allegations of grooming and recruitment. They explore how wealth, loss, and humiliation link to anxiety and depression. They discuss FDA shifts toward single pivotal-trial approvals and how accelerated pathways changed psychiatric drug clearances.

A forensic psychiatric look at the diagnoses people use to explain Jeffrey Epstein. Childhood, personality and boundary-pushing behavior are examined. Antisocial traits are weighed against anxiety, guilt and missing developmental signs. Legal context and how society interprets high-profile abuse cases are explored.

A concise dive into using pramipexole for treatment-resistant depression. Discussion covers why effective options are often underused and how to personalize care. Practical tips on dosing, titration, and managing side effects are shared. Risks like impulse issues, cardiac concerns, and sleep attacks are reviewed.

A lively discussion of pramipexole’s D3 selectivity and why that matters for motivation and anhedonia. They explore brain circuits tied to reward, causes of dopamine decline, and when pramipexole might help tough-to-treat depression. Clinical trial evidence, long‑term durability, and safety considerations get spotlighted. Closing teases dosing details to come.

Steven Hayes, psychologist and originator of Acceptance and Commitment Therapy, shares how a personal panic attack sparked decades of research and shaped ACT. He discusses his book's broad impact and how personal struggle informed clinical teaching. Conversations cover the therapy's roots, its relation to exposure, and the risks of revealing one’s own mental-health history.

Steve Hayes, clinical psychologist and originator of Acceptance and Commitment Therapy (ACT), shares how his own panic disorder shaped ACT. He recounts the limits of traditional treatments and a visceral breakthrough that changed his approach. He explains turning toward anxiety, safety behaviors, and how acceptance and metacognitive shifts inform resilience and recovery.

They compare adult and pediatric anxiety treatments and explain why some adult medications are not appropriate for children. They outline when cognitive behavioral therapy should come first and when medications may be needed. They discuss why benzodiazepines are discouraged in youth and how to talk to families about those risks. They cover sleep strategies, melatonin timing, and household medication safety.

Linda Carpenter, psychiatry professor and chief of the Mood Disorders Program at Butler Hospital/Brown, explains a new FDA-approved device for hard-to-treat depression. She describes how peripheral sensory nerves are stimulated and contrasts this approach with TMS. The conversation covers device origins, clinical trial results, and safety in clear, concise terms.